
Tempus AI stock hits $80.62 as data growth sets 2027 forecast
Tempus AI stock reached $80.62 after Q3 results. Our 2027 forecast tests data growth, reimbursement gains and the small change to 2026 guidance.
Tag
3 articles
TECHi reporting and analysis covering Healthcare Stocks. 3 articles, newest first.

Tempus AI stock reached $80.62 after Q3 results. Our 2027 forecast tests data growth, reimbursement gains and the small change to 2026 guidance.

Pfizer’s new Tukysa FDA approval follows an 11% U.S. sales decline in Q2. What the label changes, its 0.9% revenue share and the November 3 earnings checkpoint.

Abbott (ABT) stock at $95.47 after Q1 2026 guidance cut. Analyst consensus $134 target, 40% upside. Full 2027 bull/bear/base case forecast.